- $180.81m
- $20.73m
- $53.43m
Brief: Invivyd Provides Pemgarda™ Launch Update And Announces 2024 Net Product Revenue Guidance In The Range Of $150 Mln To $200 Mln
Brief: Invivyd Inc Says Substantial Doubt About Company's Ability To Continue As A Going Concern
Brief: Invivyd Files Prospectus Related To Resale, From Time To Time, By Selling Of Up To 37.7 Mln Shares Of Common Stock
Brief: Invivyd Submits Request for Emergency Use Authorization to US FDA for VYD222
Brief: Invivyd Inc Enters Into Controlled Equity Offering Sales Agreement With Cantor Fitzgerald & Co As Sales Agent
Brief: Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Brief: Invivyd Inc - Remain On Track To Have Initial Primary Endpoint Data Around Year End
Brief: Invivyd Appoints William Duke As Chief Financial Officer
Invivyd Inc reports results for the quarter ended in June - Earnings Summary
Brief: Invivyd Says On July 25, Board Increased Size Of Board From Eight Directors To Nine
Brief: Invivyd Announces Appointment Of Sara Cotter To Board Of Directors
Brief: Invivyd Announces Additional Positive Initial Data From Ongoing Phase 1 Clinical Trial Of Vyd222
Brief: Invivyd Announces Positive Initial Data From Ongoing Phase 1 Clinical Trial Of VYD222, A Monoclonal Antibody Candidate In Development For The Prevention Of Symptomatic Covid-19 In Immunocompromised People
Invivyd Inc reports results for the quarter ended in March - Earnings Summary
Brief: Invivyd Reports First Quarter 2023 Financial Results And Business Highlights
Brief: Invivyd posts Q1 EPS USD -0.32
Invivyd Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Invivyd Doses First Participants In Phase 1 Trial Of VYD222, A Novel Monoclonal Antibody Candidate For Covid-19
U.S. RESEARCH ROUNDUP- General Mills, McDonald's, Wells Fargo & Co